IL146131A0 - Treatment of neurotic disorders - Google Patents

Treatment of neurotic disorders

Info

Publication number
IL146131A0
IL146131A0 IL14613100A IL14613100A IL146131A0 IL 146131 A0 IL146131 A0 IL 146131A0 IL 14613100 A IL14613100 A IL 14613100A IL 14613100 A IL14613100 A IL 14613100A IL 146131 A0 IL146131 A0 IL 146131A0
Authority
IL
Israel
Prior art keywords
treatment
neurotic disorders
neurotic
disorders
Prior art date
Application number
IL14613100A
Other languages
English (en)
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8099796&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL146131(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of IL146131A0 publication Critical patent/IL146131A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL14613100A 1999-07-08 2000-07-07 Treatment of neurotic disorders IL146131A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA199900991 1999-07-08
PCT/DK2000/000377 WO2001003694A1 (fr) 1999-07-08 2000-07-07 Traitement de troubles nevrotiques

Publications (1)

Publication Number Publication Date
IL146131A0 true IL146131A0 (en) 2002-07-25

Family

ID=8099796

Family Applications (5)

Application Number Title Priority Date Filing Date
IL14613100A IL146131A0 (en) 1999-07-08 2000-07-07 Treatment of neurotic disorders
IL146131A IL146131A (en) 1999-07-08 2001-10-23 Pharmacological compositions containing acetylsalone for the treatment of neurotic disorders
IL170193A IL170193A (en) 1999-07-08 2005-08-09 Medicament for treatment of neurotic disorders
IL170194A IL170194A (en) 1999-07-08 2005-08-09 Medicament for treatment of neurotic disorders
IL170192A IL170192A (en) 1999-07-08 2005-08-09 Medicament for treatment of neurotic disorders

Family Applications After (4)

Application Number Title Priority Date Filing Date
IL146131A IL146131A (en) 1999-07-08 2001-10-23 Pharmacological compositions containing acetylsalone for the treatment of neurotic disorders
IL170193A IL170193A (en) 1999-07-08 2005-08-09 Medicament for treatment of neurotic disorders
IL170194A IL170194A (en) 1999-07-08 2005-08-09 Medicament for treatment of neurotic disorders
IL170192A IL170192A (en) 1999-07-08 2005-08-09 Medicament for treatment of neurotic disorders

Country Status (38)

Country Link
US (6) US7271194B2 (fr)
EP (4) EP1440691A3 (fr)
JP (1) JP4773011B2 (fr)
KR (1) KR100604176B1 (fr)
CN (1) CN1198610C (fr)
AR (1) AR021155A1 (fr)
AT (1) ATE339955T1 (fr)
AU (6) AU782514B2 (fr)
BG (4) BG110468A (fr)
BR (1) BR0011578A (fr)
CA (4) CA2687394A1 (fr)
CL (3) CL2008003939A1 (fr)
CO (1) CO5190674A1 (fr)
CY (1) CY1105806T1 (fr)
CZ (1) CZ200270A3 (fr)
DE (1) DE60030861T2 (fr)
DK (1) DK1200081T3 (fr)
EA (1) EA006555B1 (fr)
ES (1) ES2272298T3 (fr)
HK (1) HK1048069B (fr)
HR (1) HRP20010820A2 (fr)
HU (1) HUP0201791A3 (fr)
IL (5) IL146131A0 (fr)
IS (1) IS6137A (fr)
ME (2) ME00032B (fr)
MX (1) MXPA01011626A (fr)
MY (1) MY143278A (fr)
NO (4) NO329021B1 (fr)
PL (1) PL352030A1 (fr)
PT (1) PT1200081E (fr)
SI (1) SI1200081T1 (fr)
SK (1) SK82002A3 (fr)
TR (4) TR200200014T2 (fr)
TW (1) TWI232101B (fr)
UA (1) UA77645C2 (fr)
WO (1) WO2001003694A1 (fr)
YU (1) YU78701A (fr)
ZA (1) ZA200108856B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR021155A1 (es) * 1999-07-08 2002-06-12 Lundbeck & Co As H Tratamiento de desordenes neuroticos
GB0005477D0 (en) 2000-03-07 2000-04-26 Resolution Chemicals Limited Process for the preparation of citalopram
MXPA03000642A (es) 2000-07-21 2003-06-06 Lundbeck & Co As H Nuevos compuestos y su uso como inhibidores de transportes de glicina.
EA200301195A1 (ru) * 2001-05-01 2004-04-29 Х. Лундбекк А/С Применение энантиомерно чистого эсциталопрама
DK1522539T3 (da) 2001-07-31 2007-05-07 Lundbeck & Co As H Krystallinsk komposition indeholdende excitalopram
WO2004004721A1 (fr) * 2002-07-08 2004-01-15 University Of Florida Utilisation d'inhibiteurs ssri visant a prevenir ou a attenuer les troubles psychologiques en rapport avec un traumatisme
US20050137255A1 (en) * 2002-12-23 2005-06-23 H. Lundbeck A/S Crystalline escitalopram hydrobromide and methods for preparing the same
CA2511142A1 (fr) * 2002-12-23 2004-07-08 H. Lundbeck A/S Hydrobromure d'escitalopram et son procede de preparation
TR200504022T1 (tr) * 2003-03-24 2006-08-21 Hetero Drugs Limited (S)-sitalopram oksalatın yeni sıvı kristal formları.
US20090093461A1 (en) * 2003-07-02 2009-04-09 Astrazeneca Ab Methods of Treating Anxiety and Mood Disorders
US7884096B2 (en) * 2003-12-02 2011-02-08 Pharmaneuroboost N.V. Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US8304431B2 (en) * 2003-12-02 2012-11-06 Pharmaneuroboost N.V. Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US7855195B2 (en) * 2003-12-02 2010-12-21 Pharmaneuroboost N.V. Method of treating mental disorders using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
WO2007053796A2 (fr) 2005-10-14 2007-05-10 Forest Laboratories, Inc. Procedes de traitement de troubles du systeme nerveux central avec une combinaison de faible dose d'escitaloprame et de bupropion
US20070134322A1 (en) * 2005-12-14 2007-06-14 Forest Laboratories, Inc. Modified and pulsatile release pharmaceutical formulations of escitalopram
FR2912057B1 (fr) * 2007-02-07 2009-04-17 Sanofi Aventis Sa Composition pharmaceutique contenant en association le saredutant et un inhibiteur selectif de la recapture de la serotonine ou un inhibiteur de la recapture de la serotonine/norepinephrine
TW200817003A (en) * 2006-07-31 2008-04-16 Sanofi Aventis Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1143702A (fr) * 1965-03-18
GB1526331A (en) * 1976-01-14 1978-09-27 Kefalas As Phthalanes
US4436874A (en) 1981-11-19 1984-03-13 Societe D'expansion Scientifique "Expansia" Acrylic copolymers and their use in solid phase peptide synthesis
GB8419963D0 (en) * 1984-08-06 1984-09-12 Lundbeck & Co As H Intermediate compound and method
GB8607313D0 (en) * 1986-03-25 1986-04-30 Ici Plc Pharmaceutical compositions
GB8814057D0 (en) 1988-06-14 1988-07-20 Lundbeck & Co As H New enantiomers & their isolation
US4902710A (en) * 1988-12-14 1990-02-20 Eli Lilly And Company Serotonin and norepinephrine uptake inhibitors
US5114976A (en) * 1989-01-06 1992-05-19 Norden Michael J Method for treating certain psychiatric disorders and certain psychiatric symptoms
US4962128A (en) * 1989-11-02 1990-10-09 Pfizer Inc. Method of treating anxiety-related disorders using sertraline
US5296507A (en) * 1990-09-06 1994-03-22 H.Lundbeck A/S Treatment of cerbrovascular disorders
DK213290D0 (da) * 1990-09-06 1990-09-06 Lundbeck & Co As H Treatment of cerebrovascular disorders
US5708035A (en) * 1991-02-04 1998-01-13 Sepracor Inc. Methods of use and compositions of R(-) fluoxetine
AU1919592A (en) 1991-04-16 1992-11-17 National Institutes Of Health Method of treating trichotillomania and onychophagia
WO1993009769A1 (fr) 1991-11-15 1993-05-27 Sepracor, Inc. Procedes et compositions a base de fluoxetine isomere s(+) pur
EP0714663A3 (fr) * 1994-11-28 1997-01-15 Lilly Co Eli Potentialisation d'un médicament par un antagoniste du récepteur sérotonine 1A
US5627196A (en) * 1995-01-17 1997-05-06 Eli Lilly And Company Compounds having effects on serotonin-related systems
WO1996024353A1 (fr) * 1995-02-10 1996-08-15 Eli Lilly And Company Procede de traitement ou de prevention de troubles psychiatriques
US5554383A (en) * 1995-04-06 1996-09-10 Trustees Of Tufts College Veterinary method for clinically modifying the behavior of dogs exhibiting canine affective aggression
SE9501567D0 (sv) * 1995-04-27 1995-04-27 Astra Ab A new combination
DE69607904T2 (de) 1995-08-16 2000-10-05 Eli Lilly And Co., Indianapolis Potenzierung von Serotonin-Wirkstoffresponz
US5846982A (en) * 1996-06-14 1998-12-08 Eli Lilly And Company Inhibition of serotonin reuptake
US5912256A (en) * 1996-06-20 1999-06-15 Eli Lilly And Company Compounds having effects on serotonin-related systems
US5747494A (en) * 1996-06-28 1998-05-05 U C B S.A. Pharmaceutical compositions for the treatment of depressive disorders
US5958429A (en) * 1996-08-16 1999-09-28 Eli Lilly And Company Potentiation of serotonin response
ZA977967B (en) * 1996-09-23 1999-03-04 Lilly Co Eli Combination therapy for treatment of psychoses
US5776969A (en) * 1997-02-27 1998-07-07 Eli Lilly And Company Treatment of sleep disorders
US6069177A (en) * 1997-07-08 2000-05-30 The Hong Kong University Of Science And Technology 3-Hydroxy-propanamine derived neuronal reuptake inhibitors
SE9703375D0 (sv) * 1997-09-18 1997-09-18 Astra Ab A new combination
SE9703379D0 (sv) * 1997-09-18 1997-09-18 Astra Ab New compounds
JP3813820B2 (ja) * 1997-11-11 2006-08-23 ハー・ルンドベック・アクチエゼルスカベット シタロプラムの製造方法
DK0957099T3 (da) * 1998-04-15 2003-03-17 Pfizer Prod Inc Heterocykliske carboxamider
AU4850199A (en) * 1998-06-30 2000-01-17 Eli Lilly And Company Pyrrolidine and pyrroline derivatives having effects on serotonin related systems
CA2336962A1 (fr) 1998-07-13 2000-01-20 Alan Mueller Procedes et composes permettant de traiter la depression et d'autres troubles
EP1096927A4 (fr) 1998-07-16 2002-09-04 Massachusetts Inst Technology Composition pour le traitement du stress
US6579899B1 (en) 1998-07-16 2003-06-17 Massachusetts Institute Of Technology Composition for treatment of stress
US6150376A (en) * 1998-08-05 2000-11-21 Georgetown University Bi- and tri-cyclic aza compounds and their uses
SE9803158D0 (sv) * 1998-09-16 1998-09-16 Astra Ab A new composition
SE9803157D0 (sv) 1998-09-16 1998-09-16 Astra Ab A new composition
EP1123284B1 (fr) * 1998-10-20 2003-01-08 H. Lundbeck A/S Methode de preparation du citalopram
AR021509A1 (es) * 1998-12-08 2002-07-24 Lundbeck & Co As H Derivados de benzofurano, su preparacion y uso
ES2195554T5 (es) * 1999-04-14 2010-02-02 H. Lundbeck A/S Metodo para la preparacion de citalopram.
AR021155A1 (es) * 1999-07-08 2002-06-12 Lundbeck & Co As H Tratamiento de desordenes neuroticos
US6333357B1 (en) * 1999-11-05 2001-12-25 Be Able, Llc Behavior chemotherapy
UA77650C2 (en) * 1999-12-06 2007-01-15 Lundbeck & Co As H Use of serotonin reuptake inhibitor in combination with deramcyclane
GB2357762B (en) * 2000-03-13 2002-01-30 Lundbeck & Co As H Crystalline base of citalopram
CA2405025A1 (fr) * 2000-04-24 2001-11-01 Aryx Therapeutics Substances et methodes de traitement de la depression
JP2002361405A (ja) * 2000-09-25 2002-12-18 Showa Denko Kk 熱交換器の製造方法
EA200301195A1 (ru) * 2001-05-01 2004-04-29 Х. Лундбекк А/С Применение энантиомерно чистого эсциталопрама

Also Published As

Publication number Publication date
AU5806100A (en) 2001-01-30
KR20020015346A (ko) 2002-02-27
NO20100335L (no) 2002-01-07
SI1200081T1 (sl) 2007-02-28
CO5190674A1 (es) 2002-08-29
ATE339955T1 (de) 2006-10-15
EA200200137A1 (ru) 2002-06-27
BG110467A (en) 2010-01-29
NO20020062L (no) 2002-01-07
ZA200108856B (en) 2002-12-24
DE60030861T2 (de) 2007-05-03
BG110468A (en) 2010-01-29
SK82002A3 (en) 2002-07-02
TR200402275T2 (tr) 2005-03-21
MXPA01011626A (es) 2002-06-04
IS6137A (is) 2001-10-30
US20040029956A1 (en) 2004-02-12
EP1440690A2 (fr) 2004-07-28
US20040029958A1 (en) 2004-02-12
AU2005202686B2 (en) 2009-01-15
AR021155A1 (es) 2002-06-12
CA2687396A1 (fr) 2001-01-18
HUP0201791A2 (en) 2002-10-28
BG106279A (bg) 2002-08-30
AU2008264188A1 (en) 2009-05-07
JP4773011B2 (ja) 2011-09-14
EP1440691A3 (fr) 2004-08-25
UA77645C2 (en) 2007-01-15
NO20100334L (no) 2002-01-07
WO2001003694A1 (fr) 2001-01-18
US6960613B2 (en) 2005-11-01
AU2005202684A1 (en) 2005-07-14
HK1048069A1 (en) 2003-03-21
CL2008003938A1 (es) 2009-05-22
IL170194A (en) 2010-05-31
ES2272298T3 (es) 2007-05-01
PL352030A1 (en) 2003-07-28
EP1200081A1 (fr) 2002-05-02
BR0011578A (pt) 2002-03-26
TR200402277T2 (tr) 2005-01-24
IL170192A (en) 2010-04-29
EP1440691A2 (fr) 2004-07-28
CA2687394A1 (fr) 2001-01-18
IL146131A (en) 2007-02-11
EP1440689A3 (fr) 2004-08-25
IL170193A (en) 2010-04-29
US20070276035A1 (en) 2007-11-29
TR200402276T2 (tr) 2005-01-24
US7265151B2 (en) 2007-09-04
NO20020062D0 (no) 2002-01-07
TWI232101B (en) 2005-05-11
HK1048069B (zh) 2005-12-16
KR100604176B1 (ko) 2006-07-25
YU78701A (sh) 2004-03-12
CA2373757C (fr) 2010-01-05
US20050101665A1 (en) 2005-05-12
MEP2508A (xx) 2010-02-10
AU2005202685A1 (en) 2005-07-14
US20020086899A1 (en) 2002-07-04
AU2008264182A1 (en) 2009-01-29
CA2687392A1 (fr) 2001-01-18
CL2008003941A1 (es) 2009-05-22
NO20100333L (no) 2002-01-07
CA2373757A1 (fr) 2001-01-18
CZ200270A3 (cs) 2002-04-17
US7271194B2 (en) 2007-09-18
CL2008003939A1 (es) 2009-06-05
EP1200081B1 (fr) 2006-09-20
DK1200081T3 (da) 2006-12-27
HRP20010820A2 (en) 2003-08-31
EP1440689A2 (fr) 2004-07-28
EP1440690A3 (fr) 2004-08-18
MY143278A (en) 2011-04-15
EA006555B1 (ru) 2006-02-24
AU2005202684B2 (en) 2009-01-15
ME00032B (fr) 2010-02-10
DE60030861D1 (de) 2006-11-02
HUP0201791A3 (en) 2005-02-28
JP2003504332A (ja) 2003-02-04
BG110466A (en) 2010-01-29
TR200200014T2 (tr) 2002-05-21
CN1360501A (zh) 2002-07-24
US20040029957A1 (en) 2004-02-12
AU2005202686A1 (en) 2005-07-14
AU782514B2 (en) 2005-08-04
NO329021B1 (no) 2010-07-26
CN1198610C (zh) 2005-04-27
CY1105806T1 (el) 2011-02-02
AU2005202685B2 (en) 2009-01-15
PT1200081E (pt) 2007-01-31

Similar Documents

Publication Publication Date Title
GB0007193D0 (en) Treatment of movrmrnt disorders
HUP0400914A3 (en) Methods of treatment of mitochondrial disorders
IL146131A0 (en) Treatment of neurotic disorders
HK1051485A1 (zh) 增生性疾病的治療
EP1126850A4 (fr) Traitement des affections de la retine
GB9926968D0 (en) Treatment of neurological disorders
IL151765A0 (en) Hydroxyphenyl-piperazinyl-methyl-benzamide derivatives for the treatment of pain
AU7106300A (en) Treatment of skin disorders
GB2360453B (en) Treatment of skin conditions
HUP0102886A3 (en) Treatment of anxiety disorders
IL131347A0 (en) Treatment of skin disorders
AR026062A1 (es) Tratamiento de desordenes oculares
CZ20011872A3 (cs) Isonipekotamidy pro léčbu onemocnění zprostředkovaných integriny
GB0101146D0 (en) Treatment of skin conditions
GB9924942D0 (en) Treatment of movement disorders
HUP0301798A3 (en) Treatment of eating disorders using carboxyalkylethers
GB9815188D0 (en) Treatment of skin disorders
GB0017951D0 (en) Treatment of movement disorders
GB0024704D0 (en) Treatment of hyperproliferative skin disorders
GB9923551D0 (en) Treatment of neuropsychiatric disorders
AU2004235661B2 (en) Methods of treatment of mitochondrial disorders
GB9914101D0 (en) Treatment of oils
GB9914103D0 (en) Treatment of oils
GB9914106D0 (en) Treatment of oils
GB9727001D0 (en) Treatment of movement disorders